Tengion Inc. Provides Business Update and Reports First Quarter 2013 Financial Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
WINSTON-SALEM, N.C., May 15, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the first quarter ended March 31, 2013.
"We are very pleased to have achieved a significant milestone this quarter with the MPA approval for the Phase 1 trial in Sweden of the Neo-Kidney Augment.
Help employers find you! Check out all the jobs and post your resume.
WINSTON-SALEM, N.C., May 15, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today provided a business update and reported its financial results for the first quarter ended March 31, 2013.
"We are very pleased to have achieved a significant milestone this quarter with the MPA approval for the Phase 1 trial in Sweden of the Neo-Kidney Augment.
Help employers find you! Check out all the jobs and post your resume.